Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM584TM)

Drug Name

Butacaine Drug Info

Synonyms

Butacaine sulfate; Butelline; Butyn; 149-15-5; Butacaine sulphate; Butacaine sulfate [USP]; UNII-PAU39W3CVB; EINECS 205-733-1; PAU39W3CVB; p-Aminobenzoyldibutylaminopropanol sulfate; Dibutylaminopropyl p-aminobenzoate sulfate; AI3-02405; 3'-Dibutylaminopropyl 4-aminobenzoate sulfate; 1-Propanol, 3-(dibutylamino)-, 4-aminobenzoate (ester), sulfate (2:1) (salt); 3-(p-Aminobenzoxy)-1-di-N-butylaminopropane sulfate; 3-(Dibutylamino)-1-propanol p-aminobenzoate (ester) sulfate (2:1)

Indication

Disease Entry	ICD 11	Status	REF
Pain	MG30-MG3Z	Approved	[1]

Cross-matching ID

PubChem CID: 2480
ChEBI ID: CHEBI:94820
CAS Number: CAS 149-16-6
TTD Drug ID: DM584TM

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[3]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[4]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[5]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[6]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[7]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[8]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[9]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[10]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[11]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers.
3	Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
4	Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
5	Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
6	Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
7	Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
8	Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
9	Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
10	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11	In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
12	Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.